GlobeNewswire 2025-02-27 argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
GlobeNewswire 2025-02-25 argenx to Present at TD Cowen 45th Annual Healthcare Conference
GlobeNewswire 2025-02-20 argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27,...
GlobeNewswire 2024-08-28 argenx to Present at Upcoming Investor Conferences
GlobeNewswire 2024-08-26 MDA Kicks Off Muscular Dystrophy Awareness Month in September with ‘30 Days of Strength’ Campaign wi...
GlobeNewswire 2024-08-12 Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights
GlobeNewswire 2024-07-25 argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
GlobeNewswire 2024-07-18 argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 202...
GlobeNewswire 2024-07-16 argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Ge...
GlobeNewswire 2024-07-08 Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors
GlobeNewswire 2024-06-25 argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 P...
GlobeNewswire 2024-06-21 argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropat...
GlobeNewswire 2024-06-17 argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcomi...
GlobeNewswire 2024-06-13 Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
GlobeNewswire 2024-06-04 argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewswire 2024-05-09 argenx Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 2024-05-07 argenx announces results of Annual General Meeting of Shareholders
GlobeNewswire 2024-05-07 argenx to Present at BofA Securities 2024 Health Care Conference
GlobeNewswire 2024-05-02 argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
GlobeNewswire 2024-04-16 argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Pa...
GlobeNewswire 2024-03-27 argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
GlobeNewswire 2024-03-26 argenx Announces Annual General Meeting of Shareholders on May 7, 2024
GlobeNewswire 2024-03-26 argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thr...
GlobeNewswire 2024-03-07 argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of ...
GlobeNewswire 2024-02-29 argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update